These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 28333266)

  • 1. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
    Gervasoni C; Riva A; Cozzi V; Capetti A; Rizzardini G; Clementi E; Cattaneo D
    J Antimicrob Chemother; 2017 Jun; 72(6):1842-1844. PubMed ID: 28333266
    [No Abstract]   [Full Text] [Related]  

  • 2. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
    Marzolini C; Gibbons S; Khoo S; Back D
    J Antimicrob Chemother; 2016 Jul; 71(7):1755-8. PubMed ID: 26945713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological aspects of darunavir/cobicistat].
    González-Domenech CM; Palacios R; Santos J
    Enferm Infecc Microbiol Clin; 2016 May; 34 Suppl 1():30-33. PubMed ID: 28081761
    [No Abstract]   [Full Text] [Related]  

  • 4. Darunavir/cobicistat once daily for the treatment of HIV.
    Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
    Sherman EM; Worley MV; Unger NR; Gauthier TP; Schafer JJ
    Clin Ther; 2015 Sep; 37(9):1876-93. PubMed ID: 26319088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
    Bartels H; Decosterd L; Battegay M; Marzolini C
    J Antimicrob Chemother; 2017 Sep; 72(9):2574-2577. PubMed ID: 28575323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
    Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
    Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.
    Smolders EJ; Colbers EP; de Kanter CT; Velthoven-Graafland K; Drenth JP; Burger DM
    J Antimicrob Chemother; 2017 Feb; 72(2):486-489. PubMed ID: 27798211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
    Kakadiya PP; Higginson RT; Fulco PP
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133562
    [No Abstract]   [Full Text] [Related]  

  • 11. Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.
    Curran A; Pérez-Valero I; Moltó J
    AIDS Rev; 2015; 17(2):114-20. PubMed ID: 26035169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy.
    Salama E; Eke AC; Best BM; Mirochnick M; Momper JD
    J Clin Pharmacol; 2020 Dec; 60(12):1537-1550. PubMed ID: 32798276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
    N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
    Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
    HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study.
    Weidlich S; Boesecke C; Schneider J; Klinker HHF; Zink A; Balogh A; Wolf E; Bidner H; Spinner CD;
    J Antimicrob Chemother; 2020 Oct; 75(10):3082-3084. PubMed ID: 32634214
    [No Abstract]   [Full Text] [Related]  

  • 18. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
    Roberts O; Khoo S; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.
    Spinner CD; Kümmerle T; Krznaric I; Degen O; Schwerdtfeger C; Zink A; Wolf E; Klinker HHF; Boesecke C
    J Antimicrob Chemother; 2017 Sep; 72(9):2679-2681. PubMed ID: 28859438
    [No Abstract]   [Full Text] [Related]  

  • 20. Simplification of ART in a patient living with multidrug resistant HIV-1: A case report using twice daily cobicistat and darunavir.
    Brizzi MB; Novak RM; Chiampas TD
    Int J STD AIDS; 2019 Nov; 30(13):1333-1336. PubMed ID: 31631777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.